Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies. Headquartered in Bothell, Washington, the company specializes in the discovery and development of antibody-drug conjugates (ADCs) and radioligand therapies for the treatment of cancer. Its lead clinical asset is varegacestat, an oral gamma secretase inhibitor being evaluated for desmoid tumors. The company's pipeline also includes IM-1021, a ROR1-targeted ADC in Phase 1 clinical trials, and IM-3050, a FAP-targeted radioligand therapy. Immunome leverages its proprietary human memory B cell platform to identify novel therapeutic antibodies and targets. The company significantly expanded its portfolio and leadership team following a merger with Morphimmune in October 2023.
